Extracellular Vesicles Containing GAS6 Protect the Liver from Ischemia-Reperfusion Injury by Enhancing Macrophage Efferocytosis via MerTK-ERK-COX2 Signaling

doi:10.21203/rs.3.rs-4423503/v1

Download PDF

Article

Extracellular Vesicles Containing GAS6 Protect the Liver from Ischemia-Reperfusion Injury by Enhancing Macrophage Efferocytosis via MerTK-ERK-COX2 Signaling

https://doi.org/10.21203/rs.3.rs-4423503/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 10 Sep, 2024

Read the published version in Cell Death Discovery →

You are reading this latest preprint version

Hepatic ischaemia-reperfusion injury (HIRI) is a significant issue during liver transplantation and surgery, contributing to the liver failure or even mortality. Although extracellular vesicles derived from mesenchymal stem cells (MSC-EVs) have shown substantial potentials in cell replacement therapy of various organ IRIs, the precise mechanisms remain unclear. In this study, we demonstrate that systemic MSC-EVs administration is predominantly absorbed by macrophages, and verified that it could significantly reduce the liver injury and inflammatory response in mice suffered from HIRI. Furthermore, treatment with MSC-EVs induces macrophage polarization toward an anti-inflammatory phenotype. Mechanistically, proteomic profiling reveals an enrichment of growth arrest-specific 6 (GAS6) in MSC-EVs, significantly promoting the activation of myeloid-epithelial-reproductive tyrosine kinase/extracellular regulated protein kinases/cyclooxygenase 2 (MerTK/ERK/COX2) signaling pathway in macrophages and further enhancing their efferocytosis efficiency. Knockdown of GAS6 via lentiviral transfection or inhibition of MerTK using UNC2025 partially eliminates the protective effects of MSC-EVs on macrophage efferocytosis and liver injury. Overall, our findings support that MSC-EVs enriched GAS6 execute an anti-inflammation effect, highlighting that treatment bases on the modulation of macrophage function by MSC-EVs as a promising approach in IRI.

Biological sciences/Stem cells/Mesenchymal stem cells

Biological sciences/Molecular biology/Proteomics/Protein–protein interaction networks

Health sciences/Diseases/Gastrointestinal diseases/Liver diseases/Liver fibrosis

efferocytosis

mesenchymal stem cell-derived extracellular vesicles

hepatic ischaemia-reperfusion injury

macrophage

GAS6/MerTK/ERK pathway

Although significant progress has been made in the study of hepatic ischemia/reperfusion injury (HIRI), it remains an inevitable pathophysiological process and a major clinical challenge during liver transplantation and other liver surgeries[1][2][3]. HIRI encompasses two interconnected phases: local ischemic insult and oxygen free radical-induced inflammatory reperfusion injury. During the initial phase, glycogen consumption, oxygen deprivation, and adenosine triphosphate depletion lead to hepatocyte death from ischemia injury[4], while the subsequent reperfusion phase is characterized by intensified innate immunity and sterile inflammatory response[5]. Macrophages and neutrophils mediated sterile inflammatory response serves as the primary cause of organ damage[6]. Therefore, discovering more effective approaches to mitigate HIRI hold immense clinical significance.

Efferocytosis is defined as the process by which phagocytes clear dead cells[7]. Among them, macrophages, as the primary category of phagocytes, play a crucial role in the pathogenesis of HIRI[8]. Apart from recruiting host immune cells, they actively promoted inflammation resolution and tissue repair through efferocytosis. Efferocytosis relies on the recognition of eat-me signals on apoptotic cell surfaces by macrophage receptors such as myeloid-epithelial-reproductive tyrosine kinase (MerTK). Additionally, bridging molecules like growth arrest-specific 6 (GAS6) or milk fat globule epidermal growth factor-factor VIII facilitate efficient removal of dying cells[9][10][11]. Recent research has highlighted how GAS6-Mer interaction can offer both anti-inflammatory and pro-survival effects against HIRI[12][13][14], underscoring the significance of targeting phagocytic signaling for mitigating liver injury.

Mesenchymal stem cells (MSCs) are a group of adult stem cells that possess regenerative potential, multipotent capacity, and immunoregulatory effects, making them highly attractive of tissue repair[15][16]. Accumulating studies have demonstrated that MSCs exert their immunomodulatory functions through extracellular vesicles (EVs), which are submicron structures secreted by cells containing proteins, nucleic acids, and lipids[17][18][19]. Moreover, EVs derived from bone marrow MSCs (MSC-EVs) have the capability to mediate and regulate various cellular processes in target cells by transmitting their cargo via receptor-ligand interactions, endocytosis or direct fusion with the cell membrane[20][21]. Although the protective effect of MSC-EVs against HIRI has been confirmed[22][23][24], the precise regulatory mechanism remains unknown.

In the present study, we demonstrated that MSC-EVs were enriched in GAS6 and elucidated their role in promoting M2 macrophage polarization via enhancing macrophage efferocytosis in the liver. This process triggered rapid clearance of apoptotic cells and regulated the restoration of liver homeostasis after HIRI.

2.1. Isolation, characterization, and in vivo distribution of MSC-EVs

MSCs were isolated and characterized by cell surface marker detection, and multilineage differentiation potential tests. MSC-EVs were isolated as our previous description and detected using a particle analyzer. The nanoparticle tracking analysis (NTA) results showed that the size was concentrated in the range of 100-200nm (Fig. 1A). Moreover, transmission electron microscope (TEM) image displayed MSC-EVs with a typical cup-shaped morphology (Fig. 1B). Additionally, the surface markers of Alix, TSG101, CD9 were identified by immunoblot analysis which met the identification criteria of EVs (Fig. 1C).

To further investigated the distribution of MSC-EVs in mice with HIRI, we constructed the 70% HIRI mice models, followed by administered Cy5.5-stained MSC-EVs via tail vein after hepatic ischemia. At 6 hours post-surgery, mice were subjected to observation using bioluminescent in vivo imaging system (IVIS). The results demonstrated that Cy5.5 fluorescence predominantly accumulated in the injured liver of mice (Fig. 1D). Following this, euthanasia was performed and liver tissue was collected for subsequent experiments. Macrophages and hepatocytes were specifically labeled with F4/80 and Hepatocyte Nuclear Factor 4 Alpha (HNF4α) markers respectively. Co-localization between EVs-Cy5.5 and F4/80 was observed (Fig. 1E), suggesting preferential uptoke of MSC-EVs by hepatic macrophages rather than hepatocytes.

2.2. MSC-EVs treatment alleviated liver injury after HIRI

To evaluated the therapeutic effects of MSC-EVs on HIRI, we initially established a mouse model with 60 minutes of warm ischemia followed by either 6 or 24 hours of reperfusion, as our previous description[25]. Histological analysis using hematoxylin-eosin staining (H&E) staining demonstrated significant loss of hepatocyte integrity, extensive hepatocyte necrosis, and inflammatory response in the phosphate buffer saline (PBS) group. In contrast, mice pre-treated with MSC-EVs exhibited reduced hepatocyte damage (Fig. 2A). Furthermore, levels of alanine transaminase (ALT), aspartate transaminase (AST) and Suzuki scores were significantly decreased in the MSC-EVs treated group compared to the vehicle control (Fig. 2B-D), indicating that MSC-EVs effectively mitigated liver injuries. To further investigate the mitigation of hepatocyte death by MSC-EVs, we evaluated hepatic cell apoptosis through TUNEL staining and cleaved-caspase 3 (C-caspase-3) analysis. HIRI induced hepatocyte apoptosis and upregulated C-caspase-3 expression, while administration of MSC-EVs significantly attenuated hepatic apoptosis compared to the mice in the PBS group (Fig. 2E).

2.3. MSC-EVs alleviated inflammatory response promoted reparative macrophage phenotype after HIRI

HIRI is characterized by immune cell infiltration and a cascade of inflammatory reactions. Immunohistochemistry staining results revealed significantly enhanced infiltration of Ly6G⁺ neutrophils at 6 hours post-IR. Mice injected with MSC-EVs exhibited considerably less infiltration compared to mice injected with PBS (Fig. 3A). While there was no difference in the number of CD68⁺ macrophages between the two groups. Furthermore, livers treated with MSC-EVs showed significantly lower expression levels of proinflammatory genes tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1β), interleukin-17 (IL-17), and chemokines C-X-C motif chemokine ligand (CXCL1) and monocyte chemoattractant protein-1 (MCP-1) compared to those in the PBS group (Fig. 3B). Moreover, enzyme linked immunosorbent assay (ELISA) results revealed a significant reduction in serum TNF-α and IL-1β levels in the MSC-EVs treated group (Fig. 3C and D). In summary, these findings suggest that treatment with MSC-EVs effectively mitigated hepatic inflammatory response.

To further elucidated the mechanism underlying liver injury repaired by MSC-EVs, we performed immunofluorescence co-staining of CD68 and CD163 on liver tissue to identify double-positive M2 hepatic macrophages. In comparison to the PBS group, there was a significant increase in the number of CD163⁺ cells and an elevated ratio of CD163⁺/CD68⁺ cells in the MSC-EVs group. These findings suggested that MSC-EVs administration induce polarization of macrophages towards an inflammation-suppressive M2 phenotype (Fig. 3E).

2.4. Proteomic profiling identified GAS6 enrichment in Extracellular vesicles

The protein components of MSC-EVs were identified through Liquid Chromatograph Mass Spectrometer (LC-MS/MS,nanoLC-QE) analysis. Two independent preparations of MSC-EVs revealed a total of 2492 common proteins, indicating the homogeneity of our extracted samples. Additionally, GAS6 exhibited a prominent peak in both samples (Fig. 4A). Importantly, GAS6 was found to be enriched in MSC-EVs compared to cell (Fig. 4B), which showed strong association with efferocytosis, and modulated the phenotype of hepatic macrophages. Furthermore, kyoto encyclopedia of genes and genomes (KEGG) pathway analysis further demonstrated a large number of proteins associated with endocytosis, lysosome, and phagosome within MSC-EVs (Fig. 4C). Gene ontology (GO) enrichment analysis revealed the presence of proteins associated with various biological processes (BP), cellular compartments (CC), and molecular functions (MF) within MSC-EVs as depicted in Fig. 4D and F.

2.5. MSC-EVs promoted macrophage efferocytosis through activation of the MerTK/ERK/COX2 signaling pathway

To assessed the absorption efficiency of macrophages, we labeled MSC-EVs with green fluorescent PKH67 and subsequently incubated them with BMDMs marked with F-Actin for varying duration (1h, 2h, 4h, 6h). After a 2-hour incubation, it was observed that macrophages phagocytosed about 90% of the EVs, indicating rapid engulfment by MSC-EVs (Fig. 5A). Furthermore, to validated the downstream signaling pathway of GAS6, MerTK/ERK signaling pathway was found to be activated in the group pretreated with MSC-EVs; however, no significant impact on the serine/threonine-specific protein kinase (AKT) signaling pathway was observed (Fig. 5B)., macrophage efferocytosis was assessed by co-incubating BMDMs, with ACs stained with pHrodo dye. As expected, pretreatment of MSC-EVs enhanced efferocytosis of ACs by macrophages (Fig. 5C). Moreover, in situ efferocytosis was achieved by quantifying the co-localization of TUNEL-positive ACs and CD68 positive macrophages after HIRI. Consistent with our findings, administration of MSC-EVs resulted in a significant enhancement of efferocytosis efficiency by macrophages in situ (Fig. 5D). Furthermore, MSC-EVs induced phosphorylation of MerTK and ERK in BMDMs in the presence of ACs (Fig. 5E), as well as cyclooxygenase 2 (COX2) expression and prostaglandin e2 (PGE2) production (Fig. 5F and G).

2.6. GAS6 silence reversed the efficacy of MSC-EVs on macrophage efferocytosis and HIRI

To confirmed that the promotion of macrophage efferocytosis by MSC-EVs was mediated by GAS6, we performed GAS6 knockdown through transfection with GAS6-specific lentivirus. The knockdown efficiency of sh-GAS6 was verified via western blotting (Fig. 6A and B). Compared to shNC-EVs, shGAS6-EVs exhibited a reduced ability to promote efferocytosis of ACs (Fig. 6C). Furthermore, the activation of the MerTK/ERK/COX2 pathway was significantly diminished in BMDMs treated with shGAS6-EVs, both with or without coculture with ACs (Fig. 6D and F). Additionally, pretreatment with shGAS6-EVs led to a decrease in PGE2 production by BMDMs compared to shNC-EVs (Fig. 6G). In vivo experiments demonstrated that the protective effect of MSC-EVs on liver injury was largely abolished upon knockdown of GAS6 (Fig. 6H and I), as well as macrophage efferocytosis in situ (Fig. 6J). Collectively, these findings suggest that GAS6 played a crucial role in mediating MSC-EVs-induced promotion of BMDMs efferocytosis and liver injury following I/R.

2.7. MerTK and ERK inhibition reversed the efficacy of MSC-EVs on macrophage efferocytosis and HIRI.

The MerTK-specific inhibitor UNC2025 was employed to investigate the dependence of MSC-EVs therapeutic effects on the MerTK/ERK pathway. Remarkably, UNC2025 treatment significantly impeded MSC-EV-induced phagocytosis of ACs by BMDMs (Fig. 7A). Furthermore, UNC2025 treatment effectively suppressed MSC-EVs-induced phosphorylation of MerTK and ERK, as well as COX2 expression in BMDMs (Fig. 7B). UNC2025 treatment also led to a notable reduction in PGE2 production (Fig. 7C). Similarly, U0126 treatment exhibited significant inhibition of MSC-EV-induced phagocytosis of ACs by BMDMs (Fig. 7D), along with decreased COX2 expression levels (Fig. 7E). Moreover, in vivo results demonstrated that administration of UNC2025 resulted in increased liver damage compared to the MSC-EVs group. This was evidenced by an augmented area of parenchymal necrosis and elevated serum AST and ALT levels (Fig. 6F and G). TUNEL/CD68 immunofluorescence co-staining revealed that inhibition of MerTK activation markedly reduced macrophage efferocytosis in situ (Fig. 7H). Collectively, these findings strongly suggested that the efferocytic effects induced by MSC-EVs were reliant on activation of the MerTK/ERK pathway.

2.8. MSC-EVs treatment has no long-term effects on liver fibrosis.

The importance of macrophage efferocytosis in tissue remodeling and liver fibrosis development has been acknowledged[26]. In order to investigated the impact of MSC-EVs improved macrophage efferocytosis on hepatic fibrosis, HIRI mice were intravenously injected with MSC-EVs or PBS and sacrificed 7 days after surgery. Histological analyses including H&E staining, picro sirius red staining, and Alpha-smooth muscle actin (α-SMA) immunohistochemistry revealed no significant differences between the groups treated with MSC-EVs or PBS (Fig. 8A-C). Additionally, examination of fibrogenic gene expression such as transforming growth factor-β (TGF-β), collagen type I alpha 1 chain (COL1A1), α-SMA, showed no significant differences between the two groups (Fig. 8D), which was further confirmed by α-SMA immunoblot analysis (Fig. 8E).

In this study, we provided novel and significant insights into the application of MSC-EVs. Our findings demonstrated that MSC-EVs can effectively protect against the HIRI in a murine model. Furthermore, systemic administration of MSC-EVs specifically targeted hepatic macrophages rather than hepatocytes, leading to not only the activation of M2 phenotype in macrophages but also an enhancement in their efferocytosis activity. Mechanistically, our protein array analysis revealed an enrichment of GAS6 in MSC-EVs and identified MerTK as its corresponding receptor. Finally, we elucidated that the activation of MerTK/ERK/COX2 signaling pathway through direct ligand-receptor binding may be involved in modulating macrophage efferocytosis and consequently mitigating HIRI (Fig. 9).

As the predominant innate immune cell in the liver, macrophages play a pivotal role in maintaining inflammatory responses and tissue homeostasis. Macrophage infiltration and activation are both causative factors and characteristic events of HIRI[27][28][29]. The phenotype of macrophages can be influenced by the local microenvironment during disease progression, leading to their polarization into M1 or M2 macrophages. Studies have shown that diabetes/hyperglycemia specifically triggered S1P/S1PR3 signaling and exacerbated HIRI by facilitating M1 polarization and inhibiting M2 polarization[30]. Therefore, controlling the pro-inflammatory effects of macrophages is essential to prevent exacerbation of HIRI.

Previous research has demonstrated that MSCs effectively alleviated both functional impairment and pathological damage associated with IRI through the release of beneficial paracrine factors[31]. In this study, following treatment with MSC-EVs, there was no significant change in the number of infiltrated CD68⁺ macrophages compared to vehicle controls groups at 6 hours post-reperfusion. Interestingly, consistent with our group's previous findings, MSC-EVs possessed unique immunomodulatory functions by promoting the polarization of macrophages toward an M2 phenotype (CD68⁺CD163⁺)[32]. Moreover, our study demonstrated that the transcription and protein expression of cytokines (TNF-α and IL-1β) and chemokines (CXCL-1 and MCP-1) in mice suffered HIRI were reduced after administration of MSC-EVs, indicating that MSC-EVs facilitated a switch in macrophage phenotype towards a reparative state under inflammatory conditions.

GAS6 is a vitamin K-dependent protein that participates in immune regulation, inflammation, and apoptosis by binding to the TAM receptor family (Tyro3, AXL, and Mer)[33]. While much of the literature suggested that MSC-EVs influenced disease outcomes through transfer of microRNA, an earlier study by Toh et al. indicated that MSC exosome-derived proteins have the potential to modulate numerous biological processes associated with disease pathogenesis, tissue repair, and regeneration[34]. Importantly, perivascular cell-derived EVs contain GAS6, which activates the GAS6/Axl pathway in endothelial cells to promote tumor angiogenesis[35]. Indeed, pericytes have been identified as a source of MSCs precursors in vivo in multiple organs[36]. Consistent with previous report, our study clarified that GAS6 was enriched in MSC-EVs by proteomic profiling. Nevertheless, there is still a lack of understanding regarding the mechanisms involved in both EVs-GAS6 interaction with the MerTK receptor and EVs-GAS6-induced activation of downstream signaling pathway in BMDMs. Although the role of TAM receptors in phagocytosis and bacterial killing has been a subject of controversy[37], they are generally recognized to be involved in maintaining homeostasis and promoting the efferocytosis during the resolution phase of inflammation[38][39]. Recent studies have shown that deletion of MerTK nearly abolished macrophage phagocytosis of ACs by macrophages, whereas deletion of Axl, Tyro3, or both reduces macrophage phagocytosis by approximately 50%[40]. Moreover, MerTK-expressing monocytes and macrophages represent an immune-modulatory pro-restorative cell population[41][42].

In models of acute liver injury, Axl^-/- and MerTK^-/- mice demonstrated increased accumulation of ACs and more severe liver injury compared to their wild-type counterparts. This observation suggested that the process of efferocytosis, which involved the clearance of ACs, required MerTK[43]. In this study, EVs-GAS6 might be delivered to BMDMs through receptor-mediated endocytosis and subsequently recirculated to activate the MerTK pathway. To confirm that, the beneficial effects of MSC-EVs on macrophage efferocytosis were partially inhibited both and in vivo using a MerTK/ERK inhibitor. Additionally, knockdown of GAS6 using shRNA significantly diminished the effects of MSCs on macrophages. Collectively, our results indicate that GAS6 plays a role in enhancing phagocytic capacity of macrophages mediated by MSC-EVs through targeting the MerTK/ERK signaling pathway rather than AKT signaling pathway.

Fibrosis is the consequence of an excessive and abundant deposition of extracellular matrix resulting from recurrent tissue damage or dysregulation of the repair process, in which macrophages play a dual regulatory role[44]. In fact, reparative mechanisms such as efferocytosis are necessary for responding to damage, but they can be beneficial only in transient situations and harmful when excessive[45]. On one hand, efferocytosis inhibits inflammation and facilitates tissue repair during acute liver injury; on the other hand, continuous activation of this signaling pathway contributes to chronic inflammation leading to fibrosis and tumorigenesis by evoking hepatic stellate cells while inhibiting anti-tumor immunity. In our study, our findings reveal that MSC-EVs can enhance macrophage phagocytosis of ACs through temporary and effective activation of the MerTK/ERK pathway but have no effect on long-term development of liver fibrosis. Thus, as a highly promising, safe, and specific endogenous nanomedicine carrier, MSC-EVs hold broad application prospects in HIRI. Taken together, our data demonstrated the enrichment of GAS6 in MSC-EVs and its ability to activate the MerTK/ERK pathway in macrophages, leading to their polarization towards a pro-repair phenotype and enhanced efferocytosis. Consequently, this mechanism mitigated HIRI, highlighting the crucial role of GAS6 in IRI pathogenesis and providing valuable insights for clinical interventions targeting HIRI.

4.1. Mouse model of HIRI and treatment

Male C57BL/6 mice, 8–10 weeks old, were purchased from Beijing Hua Fukang Biotechnology Co.,Ltd. (Beijing, China). All animal experimental conform to the protocols approved by the Experimental Animal Ethics Committee of College of Medicine, Qingdao University (QDU-AEC-2023360). Briefly, the mice were fasted for 12 hours before surgery and anesthetized with 2% isoflurane. A midline laparotomy was performed, the blood supply of portal vein and hepatic artery in mouse liver were blocked by non-invasive vascular clip. This results in a reduction in hepatic blood flow of about 70%. Immediately after blocking 70% of the hepatic blood flow, mice (n = 5 per group) were separated randomly into five groups: sham, I/R + Vehicle (PBS,200ul), I/R + MSC-EVs (2×10¹⁰ particles/body), I/R + UNC2025 (50mg/kg) + MSC-EVs (2×10¹⁰ particles/body), sh-NC-MSC-EVs or sh-GAS6-MSC-EVs (2×10¹⁰ particles/body)[22]. Then the clip was released after approximately 60min followed by 6, 24 hours reperfusion. Liver tissue and blood specimens were collected following the reperfusion phase.

4.2. Primary Mouse BM-MSCs and BMDMs Isolation and Culture

Isolation and culture of mouse BM-derived MSCs were performed as our previous description[46]. Briefly, MSCs from femurs and tibias of 3–4 weeks old C57BL/6 mice were cultured in mouse bone marrow mesenchymal stem cell complete medium. Then, medium was changed every 2–3 days until the cells reached 80% confluence and then passaged. MSCs at the third and fourth passages were used for subsequent experiments.

For culture of primary bone marrow-derived macrophages (BMDMs), the femur and tibia bones marrow cavities of C57BL/6J mice (6–8 weeks) were flushed with PBS, which was then passed through a cell strainer. Freshly harvested cells were cultured for 7 days in high-glucose DMEM containing 10% FBS and 1% penicillin streptomycin solution and 10ng/ml recombinant mouse macrophage colony-stimulating factor (M-CSF). Fully mature BMDMs on day 7 were used for subsequent assays. Cells were cultured in 5% CO2 incubator at 37°C.

4.3. Extracellular Vesicles Isolation and Characterization

The characterization and quantification of MSC-EVs were determined by TEM analysis, Western blotting analysis, and NTA as previous description[47][48]. To separate EVs, the third or fourth generation of cells were grown to confluence, washed 3 times with PBS and then incubated in serum-free media at 37°C. After 24 hours, We collected the supernatant of cell culture and the dead cells and debris in the medium were removed via centrifugation at 2000g for 20min. Then, the supernatant filtered with 0.22µm filters. An Amicon Ultra-15 Centrifugal Filter Unit (100 kDa; Millipore, Billerica, USA) was used to concentrate medium. Finally, MSC-EVs were isolated from the concentrated supernatants using Exoquick-TC™ (System Biosciences, CA, USA) according to manufactory’s instruction.

4.4. Extracellular vesicles labeling and tracking

As previously mentioned, to observe the distribution of EVs in HIRI mice, MSC-EVs were labeled with Cyanine5.5 NHS (Cy5.5, 1:1000, Lumiprobe, Florida, USA)[46]. Stained EVs were injected into mice via tail vein immediately after ischemia. After 6 hours of reperfusion, bioluminescence pictures were captured and processed using an IVIS Lumina XRMS III in vivo imaging system (PerkinElmer, Waltham, MA, USA)., MSC-EVs were stained with PKH67, and then incubated with BMDMs for various time(1h, 2h, 4h or 6h) to observe the efficiency of BMDMs in phagocytosis of MSC-EVs. The uptake of MSC-EVs by BMDMs was photographed with an inverted fluorescence microscope.

4.5. Induction of apoptosis and labeling of neutrophil

Total neutrophils from mouse bone marrow were obtained using the Mouse Neutrophil Enrichment Kit from Solarbio Science & Technology Co., Ltd. (Beijing, China) according to the manufacturer’s specifications. This process routinely yielded a neutrophil population of 90% purity as assessed by flow cytometry for CD11b, Ly6G and Gr-1 (data not shown). For neutrophil apoptosis, cells were collected into centrifuge tubes and placed in a 55°C water bath for half an hour. The cells were then rinsed and resuspended in complete DMEM before adding them to macrophages at a 5:1 ACs: macrophage ratio. For some experiments, ACs were stained with pHrodo dye (Thermo Fisher Scientific) as described by the manufacturer’s protocol.

4.6. Efferocytosis assay

For in situ efferocytosis, the terminal deoxynucleotidyl transferase dUTP-biotin nick end labelling (TUNEL) assay from a commercially available kit (Yeasen) was used to identify hepatocyte apoptosis according to the manufacturer's instructions. After sealed with 5% BSA for 60 minutes, liver tissues were incubated with anti-CD68 (Servicebio,1:200) for a whole night at 4°C, and counterstained with DAPI. For efferocytosis, BMDMs were plated in 48-well tissue culture plates and pretreated with MSC-EVs for 2 hours. Apoptotic neutrophils were labelled with pHrodo green succinimidyl ester (Thermo Fisher Scientific) at 37°C for 45min and washed twice with PBS. Then the above two prepared cells were co-incubated at a ratio of 5:1 (ACs/Mϕ, where Mϕ denotes BMDMs) for 2 hours. Then, Nonadherent cells were washed off with PBS. And BMDMs were further stained with Actin-Trcker Red-555 (Beyotime). Images were taken using the fluorescence microscope to identify the uptake of labelled ACs and quantified using Image J software. Efferocytosis was evaluated as the percentage of pHrodo-green positive cells in all Actin-Trcker Red-555 positive cells.

4.7. Transduction of recombinant lentivirus

To obtain MSC-EV-shNC and MSC-EV-shGAS6, MSCs at passage 2 were seeded in cell culture flasks to reach 30–50% confluency, followed by transfection with NC shRNA or GAS6 shRNA using a commercial kit (General Biol, Anhui, China). After transfection for 24–48 hours, the culture medium was replaced with fresh medium. Then 2ug/ml puromycin was added to selectively enrich shRNA-positive cells. Knockdown of GAS6 were further detected by western blotting.

4.8. Proteomic analysis of MSC-EVs

Proteome profiling of MSC-EVs was performed by Suzhou PANOMIX Biomedical Tech Co. Ltd. Briefly, MSC-EV samples (50µl, obtained from 100ml MSC culture medium) were quantified and sample with 30ug proteins were performed with SDS-PAGE separation, followed by filter-aided sample preparation (FASP digestion).

LC-MS/MS analysis was performed on a timsTOF Pro mass spectrometry (Bruker) that was coupled to Nanoelute (Bruker). The mass spectrometer was operated in positive ion mode. The peptides were loaded onto a C18-reversed phase analytical column (Thermo Scientific Easy Column, 25cm long, 75µm inner diameter, 1.9µm resin) in 95% buffer A (0.1% Formic acid in water) and separated with a linear gradient of buffer B (99.9% acetonitrile and 0.1% Formic acid) at a flow rate of 300nl/min. The MS raw data for each sample were combined and searched using the MaxQuant 1.6.14 software for identification and quantitation analysis. The following options were used for protein identification: Enzyme = trypsin, Fixed modification = Carbamidomethyl (C), Dynamical modifications = Oxidation (M), Max Missed Cleavages = 2.

4.9. Immunohistochemistry (IHC)

To monitor the pathological changes in liver tissues, all samples were fixed with 4% PFA, blocked, and then treated with cleaved-caspase3 (1:200,CST), alpha-smooth muscle actin(1:200, Abcam) antibody overnight at 4°C before visualization by color development with 3,3-diaminobenzidine (DAB) (Servicebio).

4.10. Western blot analysis

Western blot was performed as previously reports. Briefly, protein samples were separated by 7.5% or 10% SDS-PAGE and transferred to PVDF membrane. Thereafter, membranes were blocked with 5% nonfat dry milk solution for 1 hour and were incubated overnight at 4°C with anti-Alix (1:1000, HUABIO), anti-TSG101 (1:1000, Abacm), anti-CD9 (1:1000, Abacm), anti-GAS6 (1:1000, Abclonal), anti-AKT1/2/3 (1:2000, HUABIO), anti-Phosopho-AKT (1:2000, HUABIO), anti-ERK1/2 (1:2000, HUABIO), anti-Phosopho-ERK1 + ERK2 (1:2000, HUABIO), anti-MerTK (1:2000, R&D), anti-Phosopho-MerTK (1:500, Abacm), anti-COX2 (1:1000, HUABIO), anti-α-SMA (1:1000, Abcam), anti-β-Actin (1:1000, Abclonal). Subsequently, the membranes were incubated with the secondary antibody for 1 hours. Then, the specific bands were visualized by an enhanced chemiluminescence reagent kit (Meilunbio). Finally, and signals were detected with an automatic chemiluminescence image analysis system (Tanon, Shanghai, China), and the expression levels of all target proteins were normalized to β-actin with ImageJ software (U.S. National Institutes of Health, Bethesda, MD, USA).

4.11. Real‑time quantitative PCR (RT‑qPCR)

Total RNA was extracted from cells using FastPure Cell/Tissue Total RNA Isolation Kit (Vazyme, Nanjing, China), and reverse transcribed to cDNA using Prime-Script First Strand cDNA synthesis kit (TaKaRa, Dalian,China) according to the manufacturer’s instructions. RT-PCR were performed according to the standard operating procedures. The relative mRNA expression levels were normalized to housekeeping gene GAPDH. The relative expression of each mRNA was calculated using the 2-ΔΔCT method. All sequences of primer are shown in Table 2.

4.12. Statistical analysis

In this study, all data were obtained from at least three independent experiments. Statistical analysis were performed using Priam 8.0 software (GraphPad, San Diego, CA, USA). Unpaired Student-t-test was used to determine differences between the two groups. Results were presented as means ± SD and differences with P values smaller than 0.05 were considered statistically significant.

Acknowledgements

This work was supported by the Shandong Provincial Natural Science Foundation grant (ZR2022MH183), the Shandong Provincial Youth Entrepreneurship Program for Colleges and Universities (2022KJ148) and Qingdao demonstration programs for science and technology to benefit the people(24-2-8-smjk-9-nsh).

Author Contributions

L.M. and C.Y. contributed equally to this work. G.D. and P.C. conceived the study and designed experiments. L.M carried out the experiments. C.Y. and G.D. helped the statistical analyses and contributed to bioinformatic analyses. G.G. performed research. X.J., M.P., Y.Y and Y.Y. performed data collation. G.D., P.C., X.L. and C.Y. contributed critical comments on the manuscript. G.D. and L.M. wrote the paper. All authors have read and approved the final manuscript. The authors also thanked the Suzhou PANOMIX Biomedical Tech Co. Ltd. for technology support.

Conflict of Interest

The authors declare no conflict of interest.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Guan Y, Yao W, Yi K, et al. Nanotheranostics for the Management of Hepatic Ischemia-Reperfusion Injury. Small 2021; 17: 2007727.
Dogan S, Aslan M. Hepatic ischemia–reperfusion injury and therapeutic strategies to alleviate cellular damage. Hepatology Research 2011; 41: 103–117.
Luan X, Chen P, Miao L, et al. Ferroptosis in organ ischemia–reperfusion injuries: recent advancements and strategies. Mol Cell Biochem. Epub ahead of print 31 March 2024. DOI: 10.1007/s11010-024-04978-2.
Zhai Y, Petrowsky H, Hong JC, et al. Ischaemia–reperfusion injury in liver transplantation—from bench to bedside. Nat Rev Gastroenterol Hepatol 2013; 10: 79–89.
Hirao H, Nakamura K, Kupiec-Weglinski JW. Liver ischaemia–reperfusion injury: a new understanding of the role of innate immunity. Nat Rev Gastroenterol Hepatol 2022; 19: 239–256.
Zhai Y, Busuttil RW, Kupiec-Weglinski JW. Liver Ischemia and Reperfusion Injury: New Insights into Mechanisms of Innate—Adaptive Immune-Mediated Tissue Inflammation. American Journal of Transplantation 2011; 11: 1563–1569.
Shi H, Moore MP, Wang X, et al. Efferocytosis in liver disease. JHEP Reports 2024; 6: 100960.
Wu S, Yang J, Sun G, et al. Macrophage extracellular traps aggravate iron overload-related liver ischaemia/reperfusion injury. British J Pharmacology 2021; 178: 3783–3796.
Li J, Chen Q, Zhang R, et al. The phagocytic role of macrophage following myocardial infarction. Heart Fail Rev 2023; 28: 993–1007.
Schilperoort M, Ngai D, Sukka SR, et al. The role of efferocytosis-fueled macrophage metabolism in the resolution of inflammation. Immunological Reviews 2023; 319: 65–80.
Zhou Y, Fei M, Zhang G, et al. Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP. Immunity 2020; 52: 357–373.e9.
Llacuna L, Bárcena C, Bellido-Martín L, et al. Growth arrest-specific protein 6 is hepatoprotective against murine ischemia/reperfusion injury. Hepatology 2010; 52: 1371–1379.
Pan G, Yang Y, Zhang J, et al. Bone marrow mesenchymal stem cells ameliorate hepatic ischemia/reperfusion injuries via inactivation of the MEK/ERK signaling pathway in rats. Journal of Surgical Research 2012; 178: 935–948.
Hu H, Cheng X, Li F, et al. Defective efferocytosis by aged macrophages promotes STING signaling mediated inflammatory liver injury. Cell Death Discov 2023; 9: 236.
Huang Y, Wu Q, Tam PKH. Immunomodulatory Mechanisms of Mesenchymal Stem Cells and Their Potential Clinical Applications. IJMS 2022; 23: 10023.
Lin F, Chen W, Zhou J, et al. Mesenchymal stem cells protect against ferroptosis via exosome-mediated stabilization of SLC7A11 in acute liver injury. Cell Death Dis 2022; 13: 271.
Wu R, Fan X, Wang Y, et al. Mesenchymal Stem Cell-Derived Extracellular Vesicles in Liver Immunity and Therapy. Front Immunol 2022; 13: 833878.
Harrell CR, Jovicic N, Djonov V, et al. Mesenchymal Stem Cell-Derived Exosomes and Other Extracellular Vesicles as New Remedies in the Therapy of Inflammatory Diseases. Cells 2019; 8: 1605.
Keshtkar S, Azarpira N, Ghahremani MH. Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine. Stem Cell Res Ther 2018; 9: 63.
Wang L, Wu Y, Yao R, et al. The role of mesenchymal stem cell-derived extracellular vesicles in inflammation-associated programmed cell death. Nano Today 2023; 50: 101865.
Kou M, Huang L, Yang J, et al. Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool? Cell Death Dis 2022; 13: 580.
Haga H, Yan IK, Borrelli DA, et al. Extracellular vesicles from bone marrow–derived mesenchymal stem cells protect against murine hepatic ischemia/reperfusion injury. Liver Transpl 2017; 23: 791–803.
Zheng J, Lu T, Zhou C, et al. Extracellular Vesicles Derived from Human Umbilical Cord Mesenchymal Stem Cells Protect Liver Ischemia/Reperfusion Injury by Reducing CD154 Expression on CD4 + T Cells via CCT2. Advanced Science 2020; 7: 1903746.
Yao J, Zheng J, Cai J, et al. Extracellular vesicles derived from human umbilical cord mesenchymal stem cells alleviate rat hepatic ischemia-reperfusion injury by suppressing oxidative stress and neutrophil inflammatory response. FASEB j 2019; 33: 1695–1710.
Shi Q. Pterostilbene alleviates liver ischemia/reperfusion injury via PINK1-mediated mitophagy. Journal of Pharmacological Sciences.
Schwabe RF, Tabas I, Pajvani UB. Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. Gastroenterology 2020; 158: 1913–1928.
Hume DA. The Many Alternative Faces of Macrophage Activation. Front Immunol; 6. Epub ahead of print 22 July 2015. DOI: 10.3389/fimmu.2015.00370.
Xu H, Zhu Y, Hsiao AW-T, et al. Bioactive glass-elicited stem cell-derived extracellular vesicles regulate M2 macrophage polarization and angiogenesis to improve tendon regeneration and functional recovery. Biomaterials 2023; 294: 121998.
Su Y, Sun X, Liu X, et al. hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype. J Hematol Oncol 2022; 15: 99.
Hu Y, Yang C, Shen G, et al. Hyperglycemia-Triggered Sphingosine‐1‐Phosphate and Sphingosine‐1‐Phosphate Receptor 3 Signaling Worsens Liver Ischemia/Reperfusion Injury by Regulating M1/M2 Polarization. Liver Transpl 2019; 25: 1074–1090.
Pan G, Yang Y, Zhang J, et al. Bone marrow mesenchymal stem cells ameliorate hepatic ischemia/reperfusion injuries via inactivation of the MEK/ERK signaling pathway in rats. Journal of Surgical Research 2012; 178: 935–948.
Xu J, Chen P, Yu C, et al. Hypoxic bone marrow mesenchymal stromal cells-derived exosomal miR ‐182‐5p promotes liver regeneration via FOXO1 ‐mediated macrophage polarization. The FASEB Journal; 36. Epub ahead of print October 2022. DOI: 10.1096/fj.202101868RRR.
Van Der Meer JHM, Van Der Poll T, Van ‘T Veer C. TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis. Blood 2014; 123: 2460–2469.
Toh WS, Lai RC, Zhang B, et al. MSC exosome works through a protein-based mechanism of action. Biochemical Society Transactions 2018; 46: 843–853.
Huang M, Liu M, Huang D, et al. Tumor perivascular cell-derived extracellular vesicles promote angiogenesis via the Gas6/Axl pathway. Cancer Letters 2022; 524: 131–143.
Luan X, Chen P, Li Y, et al. TNF-α/IL-1β-licensed hADSCs alleviate cholestatic liver injury and fibrosis in mice via COX-2/PGE2 pathway. Stem Cell Res Ther 2023; 14: 100.
Williams BJC, Craven RR, Earp HS, et al. TAM receptors are dispensable in the phagocytosis and killing of bacteria. Cellular Immunology 2009; 259: 128–134.
Mukherjee SK, Wilhelm A, Antoniades CG. TAM receptor tyrosine kinase function and the immunopathology of liver disease. American Journal of Physiology-Gastrointestinal and Liver Physiology 2016; 310: G899–G905.
Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol 2008; 8: 327–336.
Seitz HM, Camenisch TD, Lemke G, et al. Macrophages and Dendritic Cells Use Different Axl/Mertk/Tyro3 Receptors in Clearance of Apoptotic Cells. The Journal of Immunology 2007; 178: 5635–5642.
Bernsmeier C, Pop OT, Singanayagam A, et al. Patients With Acute-on-Chronic Liver Failure Have Increased Numbers of Regulatory Immune Cells Expressing the Receptor Tyrosine Kinase MERTK. Gastroenterology 2015; 148: 603–615.e14.
Triantafyllou E, Pop OT, Possamai LA, et al. MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure. Gut 2018; 67: 333–347.
Zagórska A, Través PG, Jiménez-García L, et al. Differential regulation of hepatic physiology and injury by the TAM receptors Axl and Mer. Life Sci Alliance 2020; 3: e202000694.
Dai H, Zhu C, Huai Q, et al. Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models. Journal of Hepatology 2024; S0168827824001132.
Huang H, Jiang J, Chen R, et al. The role of macrophage TAM receptor family in the acute-to‐chronic progression of liver disease: From friend to foe? Liver International 2022; 42: 2620–2631.
Xu J, Chen P, Yu C, et al. Hypoxic bone marrow mesenchymal stromal cells-derived exosomal miR ‐182‐5p promotes liver regeneration via FOXO1 ‐mediated macrophage polarization. The FASEB Journal; 36. Epub ahead of print October 2022. DOI: 10.1096/fj.202101868RRR.
Yu C, Chen P, Xu J, et al. hADSCs derived extracellular vesicles inhibit NLRP3inflammasome activation and dry eye. Sci Rep 2020; 10: 14521.
Zhang J, Li Y, Xie S, et al. Baicalein glycymicelle ophthalmic solution: Preparation, in vitro antimicrobial activities, and antimicrobial mechanism evaluations. International Journal of Pharmaceutics 2024; 654: 123964.

(Not answered)

Graphicalabstract.tif
Graphical abstract HIRI is a thorny problem after liver surgery such as liver transplantation. In a murine model of HIRI, MSC-EVs enriched GAS6 effectively enhance macrophage efferocytosis both in vivo and in vitro through the GAS6/MerTK/ERK/COX2 signaling pathway and significantly mitigate liver injury. This image was drawn by the authors.
XXXXXXXXXCDDSupplementaryfiguresandfigurelegends.docx

Download PDF

Journal Publication

published 10 Sep, 2024

Read the published version in Cell Death Discovery →

Editorial decision: revise
11 Jun, 2024
Review #1 received at journal
28 May, 2024
Reviewer #1 agreed at journal
27 May, 2024
Reviewers invited by journal
26 May, 2024
Submission checks completed at journal
16 May, 2024
First submitted to journal
16 May, 2024
Unknown event
15 May, 2024
Editor assigned by journal
15 May, 2024

You are reading this latest preprint version

Extracellular Vesicles Containing GAS6 Protect the Liver from Ischemia-Reperfusion Injury by Enhancing Macrophage Efferocytosis via MerTK-ERK-COX2 Signaling

Status:

Journal Publication

Version 1

Abstract

Figures

1. Introduction

2. Results

2.1. Isolation, characterization, and in vivo distribution of MSC-EVs

2.4. Proteomic profiling identified GAS6 enrichment in Extracellular vesicles

2.6. GAS6 silence reversed the efficacy of MSC-EVs on macrophage efferocytosis and HIRI

2.7. MerTK and ERK inhibition reversed the efficacy of MSC-EVs on macrophage efferocytosis and HIRI.

3. Discussion

4. Materials

4.1. Mouse model of HIRI and treatment

4.2. Primary Mouse BM-MSCs and BMDMs Isolation and Culture

4.3. Extracellular Vesicles Isolation and Characterization

4.4. Extracellular vesicles labeling and tracking

4.5. Induction of apoptosis and labeling of neutrophil

4.6. Efferocytosis assay

4.7. Transduction of recombinant lentivirus

4.8. Proteomic analysis of MSC-EVs

4.9. Immunohistochemistry (IHC)

4.10. Western blot analysis

4.11. Real‑time quantitative PCR (RT‑qPCR)

4.12. Statistical analysis

Declarations

References

Additional Declarations

Supplementary Files

Status:

Journal Publication

Version 1